CN Bio‘s New Animal Microphysiological System Enhances Drug Safety Testing
Table of Contents
- CN Bio’s New Animal Microphysiological System Enhances Drug Safety Testing
- Addressing the Limitations of Traditional Drug Testing
- Comparative Studies with Liver-on-a-chip models
- The Growing Importance of microphysiological Systems
- Frequently Asked Questions About Microphysiological Systems
- what is a microphysiological system (MPS)?
- How does CN Bio’s animal microphysiological system improve drug safety testing?
- what are the benefits of using Liver-on-a-chip models for drug-induced liver injury (DILI) assessment?
- How does the PhysioMimix® DILI assay enhance in vitro to in vivo extrapolation (IVIVE)?
- What is the future of microphysiological systems in drug development?
- How can I learn more about CN Bio’s animal microphysiological systems?
CN Bio has launched new animal microphysiological systems (MPS) designed to improve the accuracy of preclinical drug safety and toxicology assessments. Thes innovative models aim to bridge the gap between conventional animal studies and human trials, perhaps reducing the risk of late-stage drug failures. The new service expands upon CN Bio’s existing drug-induced liver injury (DILI) assay, recognized by the FDA, offering a more reliable method for predicting human responses to new drugs.
Addressing the Limitations of Traditional Drug Testing
Traditional in vitro methods often fall short in accurately predicting drug toxicity, while discrepancies between these methods and in vivo animal studies complicate the process of assessing safety risks for humans. This can lead to unsafe drug candidates progressing through the pipeline or potentially life-saving drugs being incorrectly abandoned. According to a 2022 study published in Applied In Vitro Toxicology, the failure rate of drugs in clinical trials due to safety concerns remains a important challenge in the pharmaceutical industry.
Did You Know? …
Microphysiological systems mimic the structure and function of human organs, providing a more realistic environment for drug testing.
Comparative Studies with Liver-on-a-chip models
CN Bio’s expanded offering allows for rapid comparative studies between human, rat, and dog-derived Liver-on-a-chip models. These assays provide a modernized workflow for generating predictive insights, mitigating the risk of costly late-stage data conflicts, and reducing needless animal use by providing early warnings of hepatotoxicity or DILI before in vivo studies. The system leverages the PhysioMimix® DILI assay to enhance in vitro to in vivo extrapolation (IVIVE) capabilities.
Benefits of the new MPS Models
- Improved prediction of human drug responses
- Reduction in late-stage drug failures
- Decreased reliance on animal testing
- Early detection of hepatotoxicity
The new service, accessible through CN Bio’s Contract Research Services (CRS), leverages the expertise of CN Bio’s scientific team to provide detailed data analysis, optimized outcomes, and data-driven conclusions. The assay supports a broad range of longitudinal and endpoint testing for DILI-specific biomarkers from single- or repeat-dosing studies over a 14-day experimental window. This provides a more comprehensive overview of underlying mechanisms of hepatotoxicity or latent effects of drug candidates to improve IVIVE assessment and streamline clinical progression.
According to a report by Grand View Research, the global organ-on-a-chip market is expected to reach $267.3 million by 2027, driven by the increasing demand for alternatives to traditional animal testing and the need for more predictive drug advancement models.
| Model | Species | Application | Benefits |
|---|---|---|---|
| Liver-on-a-chip | Human, Rat, Dog | DILI Assessment | Improved prediction, reduced animal use |
Expert Insights
Dr. Emily Richardson,Lead scientist,Safety and Toxicology at CN Bio,emphasized the importance of understanding safety risks in drug development.She noted that physiological differences between species can lead to inaccuracies in predictions,causing drugs to be wrongfully abandoned or mistakenly classified as safe. The expanded capabilities of CN Bio’s DILI assay address this gap by using commonly used animal models.
How could these new models impact the future of drug development?
What are the ethical implications of reducing animal testing in this way?
The Growing Importance of microphysiological Systems
Microphysiological systems (MPS), also known as organs-on-chips, are gaining traction as valuable tools in drug discovery and development. These systems offer a more physiologically relevant environment compared to traditional cell cultures, allowing researchers to study drug effects in a more realistic context. The use of MPS can potentially reduce the reliance on animal testing, accelerate the drug development process, and improve the prediction of drug efficacy and safety in humans.
the development of MPS technology is driven by the need for more accurate and predictive preclinical models.Traditional animal models frequently enough fail to accurately predict human responses to drugs due to physiological differences between species. MPS models, conversely, can be engineered to mimic human organs and tissues, providing a more relevant platform for drug testing.
Frequently Asked Questions About Microphysiological Systems
what is a microphysiological system (MPS)?
A microphysiological system (MPS), also known as an organ-on-a-chip, is a miniaturized, micro-engineered device that mimics the structure and function of human organs and tissues. These systems are used to study drug responses, disease mechanisms, and other biological processes in a more realistic and controlled environment than traditional cell cultures.
How does CN Bio’s animal microphysiological system improve drug safety testing?
CN Bio’s animal microphysiological system improves drug safety testing by providing a more accurate and predictive model for assessing drug toxicity. By using Liver-on-a-chip models derived from human, rat, and dog cells, the system allows for comparative studies that can identify interspecies differences and predict human responses to drugs more effectively.
what are the benefits of using Liver-on-a-chip models for drug-induced liver injury (DILI) assessment?
Liver-on-a-chip models offer several benefits for DILI assessment, including improved prediction of human drug responses, reduction in late-stage drug failures, decreased reliance on animal testing, and early detection of hepatotoxicity. These models provide a more physiologically relevant environment for studying drug effects on the liver.
How does the PhysioMimix® DILI assay enhance in vitro to in vivo extrapolation (IVIVE)?
The PhysioMimix® DILI assay enhances IVIVE by providing a more accurate and reliable platform for extrapolating in vitro data to predict in vivo responses. The assay allows for the study of drug effects in a more realistic context, taking into account the complex interactions between cells, tissues, and organs.
What is the future of microphysiological systems in drug development?
The future of microphysiological systems in drug development is promising, with increasing adoption of these technologies for drug screening, toxicity testing, and personalized medicine. As MPS models become more refined and validated, they are expected to play an increasingly significant role in accelerating the drug development process and improving the prediction of drug efficacy and safety.
How can I learn more about CN Bio’s animal microphysiological systems?
To learn more about CN Bio’s animal microphysiological systems, you can visit their official website or contact their Contract Research Services (CRS) team. They can provide detailed information about their services, capabilities, and expertise in organ-on-a-chip technology.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share this article and join the discussion below. Subscribe to our newsletter for more updates on advancements in drug development!
